PnPP-19 Peptide as a Novel Drug Candidate for Topical Glaucoma Therapy Through Nitric Oxide Release
PnPP-19 Peptide Restores Erectile Function in Hypertensive and Diabetic Animals Through Intravenous and Topical Administration.
Corpus cavernosum relaxation was evaluated using cavernous strips from male spontaneous hypertensive rats (SHR) and from streptozotocin (STZ)-diabetic mice contracted with phenylephrine and submitted to electrical field stimulation before and after incubation with PnPP-19 (10-8 mol/L, 10 minutes) or vehicle. This procedure was also used to determine cGMP/nitric oxide levels, at 8 Hz and to check the effect of PnPP-19 with sildenafil citrate. Biodistribution assays were performed using iodine 123-radiolabeled PnPP-19. In vivo erectile function was evaluated using intracavernosal pressure/main arterial pressure ratio in STZ-diabetic rats after PnPP-19 topical administration.
PnPP-19 may become a new drug able to fill the gap in the pharmacologic treatment of erectile dysfunction, especially for hypertensive and diabetic individuals RESULTS: PnPP-19 potentiated corpus cavernosum relaxation, in both control and SHR rats. SHR-cavernosal tissue treated with PnPP-19 (1-32 Hz) reached the same relaxation levels as control Wistar rats (16 and 32 Hz). PnPP-19 treatment improved cavernosal tissue relaxation in STZ-diabetic mice and rats. PnPP-19 enhanced cGMP levels in STZ-diabetic mice corpus cavernosum strips. After topical or intravenous administration in rats, 123I-PnPP-19 was mainly recruited to the penis. When topically administered (400 μg/rat), PnPP-19 restores erectile function in STZ-diabetic rats, also improving it in healthy rats by increasing the intracavernosal pressure/main arterial pressure ratio. PnPP-19 exhibited an additive effect when co-administered with sildenafil, showing a novel mode of action regardless of phosphodiesterase type 5 inhibition.PnPP-19 seems to be an indicated drug to be tested to treat ED in diabetic and hypertensive patients.PnPP-19, although active by topical application and showing safety to human beings (not shown), has low permeability, about 10% of the applied dose.Our results showed that PnPP-19 may emerge as a potent new drug that can be topically administered, becoming a promising alternative for erectile dysfunction treatment. Nunes da Silva C, Pedrosa Nunes K, De Marco Almeida F, et al. PnPP-19 Peptide Restores Erectile Function In Hypertensive And Diabetic Animals Through Intravenous And Topical Administration. J Sex Med 2019;16:365-374.
PNPP |
|||
C6959-1000 | ApexBio | 1g | 40 EUR |
PNPP |
|||
C6959-500 | ApexBio | 500mg | 28 EUR |
PNPP |
|||
T16554-10mg | TargetMol Chemicals | 10mg | Ask for price |
PNPP |
|||
T16554-1g | TargetMol Chemicals | 1g | Ask for price |
PNPP |
|||
T16554-1mg | TargetMol Chemicals | 1mg | Ask for price |
PNPP |
|||
T16554-50mg | TargetMol Chemicals | 50mg | Ask for price |
PNPP |
|||
T16554-5mg | TargetMol Chemicals | 5mg | Ask for price |
PNPP |
|||
HY-15928 | MedChemExpress | 1g | 142.8 EUR |
pNPP Reagent |
|||
GWB-Q00238 | GenWay Biotech | 100 ml | Ask for price |
pNPP Reagent |
|||
GWB-Q00239 | GenWay Biotech | 500 ml | Ask for price |
PNPP Substrate |
|||
F008-22 | Cygnus Technologies | 22 ml | 216 EUR |
pNPP Substrate |
|||
X156-11ML | Arbor Assays | 11ML | 218 EUR |
pNPP for ELISA |
|||
42R-1005 | Fitzgerald | 500 ml | 300 EUR |
PNPP sodium salt |
|||
GX9577-25 | Glentham Life Sciences | 25 | 151.6 EUR |
PNPP sodium salt |
|||
GX9577-5 | Glentham Life Sciences | 5 | 46.6 EUR |
PNPP Liquid Substrate |
|||
F008-100 | Cygnus Technologies | 100 ml | 280.8 EUR |
PNPP Liquid Substrate |
|||
F008-1000 | Cygnus Technologies | 1000 ml | 890.4 EUR |
pNPP Disodium Hexahydrate |
|||
21530110-1 | Glycomatrix | 1 g | 44.84 EUR |
pNPP Disodium Hexahydrate |
|||
21530110-2 | Glycomatrix | 5 g | 145.5 EUR |
pNPP Disodium Hexahydrate |
|||
21530110-3 | Glycomatrix | 25 g | 237.01 EUR |
PNPP, Disodium Hexahydrate |
|||
P653443 | Toronto Research Chemicals | 1g | 80 EUR |
pNPP Phosphatase Assay Kit |
|||
POPN-01K | BioAssay Systems | 1000 | 408 EUR |
pNPP Phosphatase Assay Kit |
|||
POPN-500 | BioAssay Systems | 500 | 259 EUR |
pNPP Phosphatase Assay Kit |
|||
Z5030009 | Biochain | 500 assays | 213 EUR |
pNPP Phosphatase Assay Kit |
|||
Z5030010 | Biochain | 1,000 assays | 213 EUR |
pNPP-Na (para-Nitrophenylphosphate) |
|||
NB0365 | Bio Basic | 5g | 78.79 EUR |
PNPP sodium salt, 5mg tablets |
|||
GX3711-100 | Glentham Life Sciences | 100 | 219.7 EUR |
PNPP sodium salt, 5mg tablets |
|||
GX3711-100EA | Glentham Life Sciences | 100 EA | 302.4 EUR |
ELISA substrate: pNPP for ALP |
|||
3652-P10 | Mabtech AB | 120 ml | 120.75 EUR |
OOSA09569-100ML - pNPP Accessory Reagent |
|||
OOSA09569-100ML | Aviva Systems Biology | 100ml | 169 EUR |